Literature DB >> 28474229

Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study.

Soo-Jeong Kim1,2, Sophia Shonka2, William P French1, Jennifer Strickland2, Lindsey Miller2, Mark A Stein3,4,5.   

Abstract

Attention deficit/hyperactivity disorder (ADHD) symptoms are common in youth with autism spectrum disorders (ASD) and are frequently treated with stimulant medications. Twenty-seven children were randomized to different dose titration schedules, and ADHD symptoms, tolerability, and aberrant behaviors were assessed weekly during a 6-week trial with long-acting liquid methylphenidate (MPH). MPH at low to moderate doses was effective in reducing ADHD symptoms and was well tolerated in young children with ASD and ADHD. Future studies are needed to assess generalization and maintenance of efficacy.

Entities:  

Keywords:  ADHD; ASD; Attention deficit hyperactivity disorder; Autism spectrum disorder; Methylphenidate

Mesh：

Substances：

Year:  2017        PMID： 28474229     DOI： 10.1007/s10803-017-3125-1

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN： 0162-3257


  20 in total

1.  Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder.

Authors:  Thomas W Frazier; Paul T Shattuck; Sarah Carter Narendorf; Benjamin P Cooper; Mary Wagner; Edward L Spitznagel
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-12-13       Impact factor: 2.576

2.  Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data.

Authors:  J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-07       Impact factor: 8.829

3.  Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders.

Authors:  Douglas O Lee; Opal Y Ousley
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-12       Impact factor: 2.576

4.  Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.

Authors:  R A Barkley; M B McMurray; C S Edelbrock; K Robbins
Journal:  Pediatrics       Date:  1990-08       Impact factor: 7.124

5.  Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.

Authors:  P J Santosh; G Baird; N Pityaratstian; E Tavare; P Gringras
Journal:  Child Care Health Dev       Date:  2006-09       Impact factor: 2.508

6.  Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children.

Authors:  M Campbell; B Fish; R David; T Shapiro; P Collins; C Koh
Journal:  J Autism Child Schizophr       Date:  1972 Oct-Dec

7.  Sleep and behavior problems in school-aged children.

Authors:  M A Stein; J Mendelsohn; W H Obermeyer; J Amromin; R Benca
Journal:  Pediatrics       Date:  2001-04       Impact factor: 7.124

8.  A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.

Authors:  Kimberly A Stigler; Lael A Desmond; David J Posey; Ryan E Wiegand; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2004       Impact factor: 2.576

9.  Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.

Authors:  Adelaide S Robb; Robert L Findling; Ann C Childress; Sally A Berry; Heidi W Belden; Sharon B Wigal
Journal:  J Atten Disord       Date:  2014-05-29       Impact factor: 3.256

10.  Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.

Authors:  Deborah A Pearson; Cynthia W Santos; Michael G Aman; L Eugene Arnold; Charles D Casat; Rosleen Mansour; David M Lane; Katherine A Loveland; Oscar G Bukstein; Susan W Jerger; Perry Factor; Salome Vanwoerden; Evelyn Perez; Lynne A Cleveland
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-06       Impact factor: 2.576
View more
  7 in total

1.  Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Authors:  Deborah A Pearson; Cynthia W Santos; Michael G Aman; L Eugene Arnold; David M Lane; Katherine A Loveland; Rosleen Mansour; Anthony R Ward; Charles D Casat; Susan Jerger; Russell J Schachar; Oscar G Bukstein; Lynne A Cleveland
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-07-09       Impact factor: 2.576

Review 2.  Autism Spectrum Disorders and ADHD: Overlapping Phenomenology, Diagnostic Issues, and Treatment Considerations.

Authors:  Kevin M Antshel; Natalie Russo
Journal:  Curr Psychiatry Rep       Date:  2019-03-22       Impact factor: 8.081

Review 3.  Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents.

Authors:  Ekaterina Stepanova; Susannah Dowling; Molly Phelps; Robert L Findling
Journal:  Dialogues Clin Neurosci       Date:  2017-12       Impact factor: 5.986

Review 4.  Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder.

Authors:  Nermin Eissa; Mohammed Al-Houqani; Adel Sadeq; Shreesh K Ojha; Astrid Sasse; Bassem Sadek
Journal:  Front Neurosci       Date:  2018-05-16       Impact factor: 4.677

5.  Shank2 Mutant Mice Display Hyperactivity Insensitive to Methylphenidate and Reduced Flexibility in Social Motivation, but Normal Social Recognition.

Authors:  Elodie Ey; Nicolas Torquet; Fabrice de Chaumont; Julie Lévi-Strauss; Allain-Thibeault Ferhat; Anne-Marie Le Sourd; Tobias M Boeckers; Thomas Bourgeron
Journal:  Front Mol Neurosci       Date:  2018-10-04       Impact factor: 5.639

6.  Paving Plant-Food-Derived Bioactives as Effective Therapeutic Agents in Autism Spectrum Disorder.

Authors:  Natália Cruz-Martins; Cristina Quispe; Celale Kırkın; Ezgi Şenol; Aslı Zuluğ; Beraat Özçelik; Adedayo O Ademiluyi; Olubukola Helen Oyeniran; Prabhakar Semwal; Manoj Kumar; Farukh Sharopov; Victor López; Francisco Les; Iulia-Cristina Bagiu; Monica Butnariu; Javad Sharifi-Rad; Mohammed M Alshehri; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-08-21       Impact factor: 6.543

Review 7.  Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review.

Authors:  Noa Tsujii; Masahide Usami; Noriyuki Naya; Toshinaga Tsuji; Hirokazu Mishima; Junko Horie; Masakazu Fujiwara; Junzo Iida
Journal:  Neurol Ther       Date:  2021-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.